Advaxis gets patent in Japan for cancer immunotherapy

Advaxis (ADXS) has received a patent in Japan that covers the use of the company's ADXS-HPV immunotherapy product for the treatment of late-stage cervical cancer.

The IP is set to last until 2028.

Advaxis has over 40 patents worldwide and over 40 pending.

Shares are +6.6%. (PR)

Comments (1)
  • osty
    , contributor
    Comments (24) | Send Message
    Good news does not always translate into a higher pps for adxs.Show me the money.
    18 Mar 2014, 10:33 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs